The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.
The conversation is about finding the best quality and price for a saw palmetto supplement for hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses hair regrowth using Scandinavian Biolabs products, biotin pills, a dermaroller, rosemary oil, and a silicone head cleaner. The user observes weak hair regrowth and seeks opinions on the results.
L'Oreal Serioxyl and Garnier Fructus Stemoxydine are compared for effectiveness in hair loss treatment. The user considers switching from Serioxyl to the cheaper Garnier Fructus but is unsure about its effectiveness and stemoxydine percentage.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
A hair transplant experienced by FC Barcelona goalkeeper Ter Stegen, who reportedly saw improved confidence and performance following the procedure. People discussed finasteride as an alternative treatment option for those unable to afford a transplant.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.
Redensyl is being discussed as a potential substitute for minoxidil for hair growth after a brand switched from minoxidil to redensyl. The user is inquiring about the effectiveness of redensyl compared to minoxidil.
Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.
Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.
The conversation is about a user complaining about the strong smell of a stemoxydine serum used for hair loss. Other users suggest that the product might be counterfeit due to its unpleasant odor.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.